When health solutions become suddenly and overwhelmingly popular, there is increased demand on communication channels that impact customer experience and solution access.
Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave of digitisatio
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh